Bothell-based shingles vaccine maker Curevo Vaccine has named Guy De La Rosa as its chief medical officer.
The biotech announced the hire earlier this month. De La Rosa is joining Curevo from Boston-area biotech Enanta Pharmaceuticals, where his most recent role was executive medical director for infectious diseases.
“The Curevo team is excited to welcome Dr. De La Rosa to the company,” George Simeon, Curevo’s CEO, said in a release. “Guy, with his 20-plus years of experience directing clinical trials in the infectious disease space, will immediately bring a positive impact.”
De La Rosa spent more than two years at Enanta, according to his LinkedIn page, before which he spent more than two years at the Japanese pharmaceutical giant Takeda, where he held the role of senior medical director. Before Takeda, he spent about 11 years at Johnson & Johnson's pharmaceutical arm Janssen.
De La Rosa got is M.D. at the University of Panama School of Medicine and did his residency in Boston, Curevo said.
Curevo, founded in 2017, is developing a vaccine called CRV-101 aimed at shingles. The vaccine is currently in phase 2 clinical trials with 678 subjects, according to the company. Curevo is also investigating the vaccine's use in protecting immunocompromised children against chickenpox. The biotech is working with the Seoul, South Korea-based Mogam Institute for Biomedical Research in developing its vaccines.
“It’s an exceptionally productive team developing a very promising vaccine, and I’m excited to work with all of them to bring CRV-101 into use as quickly as we can,” De La Rosa said in a news release.
Curevo raised a $60 million Series A round in February 2022. The company added $26 million to that round in November. Simeon said in a release announcing the additional funding that Curevo plans to get data from its phase 2 trials early this year.
